Copyright
©The Author(s) 2021.
World J Gastroenterol. Apr 14, 2021; 27(14): 1497-1506
Published online Apr 14, 2021. doi: 10.3748/wjg.v27.i14.1497
Published online Apr 14, 2021. doi: 10.3748/wjg.v27.i14.1497
Figure 1 Flowchart of patient inclusion.
CHB: Chronic hepatitis B; NAs: Nucleos(t)ide analogs.
Figure 2
Distribution of age and consolidation periods of patients with hepatitis B e antigen loss.
Figure 3 Cumulative virological relapse rates.
Cumulative virological relapse rates in A: Hepatitis B e antigen (HBeAg) loss patients with hepatitis B surface antigen at cessation ≥ 100 IU/mL and < 100 IU/mL; B: HBeAg loss patients with consolidation periods ≥ 24 mo and < 24 mo. HBsAg: Hepatitis B surface antigen.
Figure 4 Cumulative virological relapse rates in patients with hepatitis B e antigen loss and seroconversion.
HBeAg: Hepatitis B e antigen.
- Citation: Xue Y, Zhang M, Li T, Liu F, Zhang LX, Fan XP, Yang BH, Wang L. Exploration of nucleos(t)ide analogs cessation in chronic hepatitis B patients with hepatitis B e antigen loss. World J Gastroenterol 2021; 27(14): 1497-1506
- URL: https://www.wjgnet.com/1007-9327/full/v27/i14/1497.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i14.1497